UK Regulators Begin Review of Taletrectinib for Lung Cancer Treatment

The regulatory move follows a strategic collaboration established in January 2026, which granted Eisai rights to distribute the oral inhibitor across several international markets, including Europe and the Middle East. The application relies on clinical data from the TRUST-I and TRUST-II studies, which demonstrated the therapy's efficacy in addressing the specific genetic mutation found in approximately 2% of non-small cell lung cancer patients. Updated results presented at the American Association for Cancer Research earlier this year further supported the safety profile of the drug.

David Hung, CEO of Nuvation Bio, noted that the validation represents a significant milestone in expanding global access to the treatment. With regulatory reviews already underway at the European Medicines Agency and prior approvals secured in the United States, Japan, and China, the company is positioning the drug as a core option for patients facing disease progression. The MHRA will now conduct a targeted assessment, leveraging existing evaluations from international reference bodies to determine whether to authorize the medicine for the U.K. market.